Worldwide Clinical Trials Executive and Leadership Team

Daniel Gizachew, the Chief Executive Officer at Worldwide Clinical Trials, directs the overarching strategic vision for global clinical development operations. This leadership role involves aligning preclinical and Phase I-IV service offerings with the evolving needs of the biotechnology and pharmaceutical sectors. By prioritizing innovation in Neuroscience and Rare Diseases, the Chief Executive Officer ensures the organization maintains a competitive edge in the global CRO market. Daniel Gizachew oversees the integration of bioanalytical sciences across all business units to drive consistent project delivery. Through rigorous oversight of corporate performance, the Chief Executive Officer fosters a culture of scientific excellence and operational efficiency. This executive leadership supports long-term growth by expanding the reach of clinical research initiatives across North American and international markets. Ultimately, the Chief Executive Officer secures the company's position as a premier partner for complex drug development programs.

Barry Lederman, the Chief Financial Officer & Chief Financial Officer, Private Equity Private Equity at Worldwide Clinical Trials, directs the financial architecture and capital allocation strategies for the organization. This role involves managing fiscal health while supporting the expansion of clinical development services across global markets. Barry Lederman oversees financial reporting, budgeting, and investment strategies that sustain the company's mid-sized CRO model. By analyzing market trends in the pharmaceutical and biotechnology sectors, the Chief Financial Officer & Chief Financial Officer, Private Equity Private Equity ensures the availability of resources for late-phase studies and real-world evidence projects. This leadership position requires close collaboration with the Board to optimize capital structures and drive sustainable revenue growth. Through disciplined financial oversight, the Chief Financial Officer & Chief Financial Officer, Private Equity Private Equity strengthens the company's ability to invest in cutting-edge bioanalytical sciences and therapeutic research infrastructure.

Keya Watkins, the President, Oncology at Worldwide Clinical Trials, directs the strategic development and execution of clinical trials within the oncology therapeutic area. This role involves overseeing the design and implementation of complex Phase I-IV studies for innovative cancer therapies. Keya Watkins manages a specialized team of clinical experts to ensure the delivery of high-quality data and regulatory compliance. By integrating real-world evidence and bioanalytical insights, the President, Oncology accelerates the development of life-saving treatments for patients. This leadership position requires constant engagement with biotechnology partners to tailor research programs to specific oncology indications. Through the expansion of clinical capabilities, the President, Oncology drives the company's market impact in the competitive cancer research landscape. This executive function ensures that oncology projects remain on schedule and within budget, ultimately supporting the organization's commitment to advancing medical science through rigorous clinical investigation and patient-centric trial design.

Alessandra Vignola, the President, Cardiovascular & Metabolic Business Unit at Worldwide Clinical Trials, directs the strategic growth and operational delivery of clinical research programs focused on heart health and metabolic disorders. This role involves overseeing the end-to-end management of preclinical and late-phase studies for global pharmaceutical clients. Alessandra Vignola architects specialized research protocols that address the unique challenges of cardiovascular and metabolic disease development. By leveraging deep therapeutic expertise, the President, Cardiovascular & Metabolic Business Unit ensures the successful execution of complex clinical trials. This leadership position requires managing cross-functional teams to deliver high-quality data that supports regulatory submissions and post-approval evidence generation. Through the expansion of the business unit's capabilities, the President, Cardiovascular & Metabolic Business Unit drives the company's reputation as a leader in these critical therapeutic areas. This executive function ensures that all cardiovascular and metabolic research initiatives align with the highest standards of scientific rigor and operational efficiency.

Lisa Skorets, the Chief of Staff, Gcd at Worldwide Clinical Trials, manages the operational synchronization of global clinical development functions. This role involves streamlining communication between executive leadership and departmental heads to ensure seamless execution of Phase I-IV studies. Lisa Skorets architects internal workflows that enhance the delivery of preclinical and bioanalytical services. By coordinating cross-functional initiatives, the Chief of Staff, Gcd optimizes resource allocation across diverse therapeutic areas including Oncology and Metabolic research. This leadership position requires constant monitoring of project milestones to maintain high performance standards. Through the implementation of strategic operational frameworks, the Chief of Staff, Gcd supports the organization's mission to accelerate drug development timelines. This executive function drives organizational agility, ensuring that global teams remain aligned with corporate objectives while navigating the complexities of international clinical trial regulations and site management.

Joy Clark, the Chief People Officer at Worldwide Clinical Trials, architects the human capital strategy to attract and retain top-tier scientific and clinical talent. This role involves cultivating a high-performance culture that supports the delivery of complex Phase I-IV clinical development services. Joy Clark oversees global talent acquisition, professional development programs, and organizational design to ensure the workforce remains equipped for advancements in Oncology and Neuroscience research. By aligning human resources initiatives with the company's mission, the Chief People Officer drives employee engagement and operational excellence. This leadership position requires managing diverse teams across international regions to maintain consistent service quality. Through the implementation of robust performance management systems, the Chief People Officer supports the growth of the organization's bioanalytical and clinical expertise. Ultimately, the Chief People Officer ensures that the company's most valuable asset—its people—remains focused on delivering superior outcomes for pharmaceutical partners.